Re-Examining the “Risk” Narrative of Mushroom Microdosing

The recent PBS NewsHour piece on microdosing mushrooms calls attention to an important topic — the fact that poison control centre calls and emergency room visits linked to psilocybin or “magic” mushrooms have increased in recent years.  That headline can easily spark alarm and suggest that microdosing is inherently dangerous. But when we look closer at the data and context, the story is more nuanced. In fact, it may be that responsible microdosing — at low doses, with proper sourcing and education — remains a low-risk practice, and one that deserves thoughtful discussion rather than fear-mongering.

What the article actually reports
Here are some of the key facts the article and associated data present:

• According to a recent study of the U.S. Poison Data System (2013-2022), calls for psilocybin-containing substances (alone or with co-ingestants) increased from 477 in 2013 to 1,441 in 2022 — roughly a 3-fold increase.
• Most of the increase started around 2019.
• The study emphasizes that dose and frequency were not captured — i.e., it cannot reveal how many of these calls were from micro-doses vs. full doses, or exact context of ingestion.
• The article highlights that while the number of calls is increasing, they remain far lower than comparable calls for non-psilocybin mushrooms or toxic plants.
• The article frames the rise as concerning and points to the possibility of increased “harm” as use becomes more common.

Where the narrative needs more balance
While the article raises an important warning flag, several aspects deserve a more balanced viewpoint:

1. Correlation not equal to causation
   The increase in poison-control calls does not necessarily mean microdosing is unsafe per se. It could reflect greater awareness, better reporting, more users, more public conversation, changes in legal status/availability, or other confounding factors. The article itself notes limitations in the dataset (e.g., dose unknown).

   In other words: if more people are using psilocybin or mushrooms — or more aware of it — then even if risk per user remains low, total calls may go up.

2. Microdosing vs full-dose use are conflated
   The dataset lumps all psilocybin exposures together – from full recreational doses, accidental ingestions (especially in children), unclear substance quality, co-ingestion with other drugs, etc. The dataset does not distinguish “microdosing” (low, sub-perceptual dosing) from higher-dose use.

   Thus using this dataset to claim that microdosing (at responsible levels) is unsafe is scientifically weak.

3. Quality of source / uncontrolled context
   Many exposures likely involve unregulated products (unknown dose/purity), self-medication without proper guidance, co-use of other substances, or accidental ingestion (especially children). These scenarios are very different from a structured, intentional microdosing regimen.

   Without parsing out context (dose, intent, set/setting, source, co-drugs), we can’t generalize from “calls increased” to “microdosing is risky.”

4. Lack of denominator / baseline risk
   The article shows counts of exposures rising, but not the number of actual users, nor the rate per user, nor how many of those users experienced actual harm, nor how many harm events resulted from microdosing. Without this, we lack a proper risk-assessment framework.

   For example: if usage rose five-fold, but poison-control calls rose three-fold, the per-user risk may have decreased.

5. Context of therapeutic and anecdotal experience is missing
   The article focuses on potential harms, but does not engage deeply with the growing body of anecdotal and early scientific data suggesting potential benefits of low-dose psychedelics (including microdosing) for mood, creativity, focus, and wellness. While not fully proven, the omission skews tone.

   For readers interested in well-informed discussion, a balanced article would address both side-effects and potential positive outcomes, under responsible practices.

Why I believe microdosing can be safe — with the right framework
Given the above critique, I want to offer why I (and my collaborators) believe that microdosing — when done with care, intention, and respect for safety — can be a low-risk, potentially beneficial practice. (Again: not a guarantee, and individual risk varies; consult qualified professionals.)

• Very low doses = minimal perceptual disruption
  The essence of microdosing is to take a dose well below the threshold of full psychedelic effect. The goal is not “trip” but subtle enhancement of mood, cognition, creativity, or well-being. By staying in that low dose window, many of the acute perceptual/psychological risks of full doses (e.g., intense altered state, disorientation) are largely avoided.

• Controlled environment + regular schedule
  In a structured regimen (e.g., fixed dose every few days or weeks, under monitoring), the user can observe how they’re responding, calibrate dose, monitor side-effects, and stop if needed. This reduces risk vs. ad-hoc usage.

• Proper sourcing / education / set & setting
  Risk skyrockets when substances are unknown purity, when user lacks accurate dosing tools, when they combine with other drugs/alcohol, or when they are in chaotic or unsafe environment. Educating users on safety, ensuring good sourcing, avoiding polydrug use, having integration practices all reduce risk significantly.

• Emerging supportive data
  Though the research base is still early, there are growing reports that microdosing may support mood, creativity, resilience, neural plasticity and wellness when done responsibly. (I’ll note that full clinical validation is still underway.)

  For example, research into full-dose psychedelics suggests relatively low physical toxicity and comparatively low addiction potential (though not zero). The microdose context may reduce risk further.

  (This is one reason I believe the alarm in the PBS article should be tempered.)

• Harm-reduction culture
  Rather than blanket prohibition or fear, promoting a harm-reduction mindset helps set realistic expectations, encourages proper guidance, discourages misuse (like high doses, mixing substances, self-medicating without monitoring). This culture empowers safer use.

Suggested guidelines for safer microdosing
Here are some suggested best-practices for those exploring microdosing (again, for educational purposes only):

1. Start with low dose, wait, observe — e.g., a fraction (10% or less) of a full dose; monitor how you feel, note subtle differences, side-effects, etc.

2. Keep a log — dose, date, what you did, how you felt, any effects (positive or negative).

3. Use a consistent schedule — many protocols use e.g., every third day, or two out/one in, etc — and avoid daily continuous microdosing to prevent tolerance or over-use.

4. Avoid mixing with other significant psychoactive drugs/alcohol — adding other substances can increase unknown risks.

5. Ensure good set & setting — even for a microdose, your mindset (why you’re doing it) and environment matter.

6. Have integration practices — journal, reflect, notice changes in mood/behaviour/creativity; ask yourself if it still aligns with your goal.

7. Stop if you notice adverse effects — changes in sleep, mood swings, anxiety, unexpected perceptual shifts, physical symptoms.

8. Stay informed and cautious — track latest research, know local laws/regulations, consult professionals when in doubt.

How to interpret the PBS article more productively
Instead of seeing it as a blanket “microdosing is dangerous” piece, here’s a more constructive takeaway:

• The article reminds us that any substance, even one with emerging safety data, can lead to increased medical calls when usage expands rapidly. It’s a caution flag — not a verdict.

• It highlights the importance of monitoring, data collection, and public health surveillance as microdosing becomes more widely practiced.

• It invites communities (users, educators, dispensaries, researchers) to be proactive about safe use, good guidance, and harm reduction — rather than assume “since it’s low dose, no risk.”

• It underscores that microdosing does not equal zero risk, and that irresponsible use (unknown dose/purity, mixing, lack of supervision) can lead to problems — exactly what poison control centres likely are seeing.

Conclusion
The rising number of poison control centre calls related to psilocybin mushrooms is worth attention — but it should not be taken as definitive proof that responsible microdosing is unsafe. When done with intention, low dose, proper sourcing, good education and monitoring, microdosing can be a low-risk tool in a broader wellness or cognitive toolkit.

What we should aim for is balanced journalism and informed public conversation — one that acknowledges both the emerging benefits and the risks, encourages safe practices, and builds community infrastructure (education, integration, research) rather than stoking fear.

As the field evolves, so too must our frameworks for understanding what “safe” means in the context of psychedelics — including microdosing. The future may hold more refined protocols, more rigorous clinical studies, and clearer best practices. Until then, users, educators and advocates should proceed with both optimism and caution.